Ambrx’s Innovative Antibody Drug Conjugate (ADC) US IND Active

SAN DIEGO, Aug. 17, 2016 /PRNewswire/ -- Ambrx announced today that their ARX788 US IND is now active. ARX788 is Ambrx's...

Ambrx closes $45M round of financing

SAN DIEGO, Aug. 4, 2016 /PRNewswire/ -- Ambrx, Inc., a clinical stage biotechnology company that discovers and develops first-in-class and best-in-class optimized protein...

Ambrx and Zhejiang Medicine Co. Ltd initiated ARX788 First-In-Human phase I clinical trial in cancer patients